SEARCH

SEARCH BY CITATION

References

  • 1
    Uchida Y & Tomonaga M (1989) Neurotrophic action of Alzheimer’s disease brain extract is due to the loss of inhibitory factors for survival and neurite formation of cerebral cortical neurons. Brain Res 481, 190193.
  • 2
    Uchida Y, Takio K, Titani K, Ihara Y & Tomonaga M (1991) The growth inhibitory factor that is deficient in the Alzheimers-disease brain is a 68-amino acid metallothionein-like protein. Neuron 7, 337347.
  • 3
    Palmiter RD, Findley SD, Whitmore TE & Durnam DM (1992) MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci U S A 89, 63336337.
  • 4
    Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP & Palmiter RD (1994) Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33, 72507259.
  • 5
    Nakajima K & Suzuki K (1995) Immunochemical detection of metallothionein in brain. Neurochem Int 27, 7387.
  • 6
    Choudhuri S, Kramer KK, Berman NE, Dalton TP, Andrews GK & Klaassen CD (1995) Constitutive expression of metallothionein genes in mouse brain. Toxicol Appl Pharmacol 131, 144154.
  • 7
    Masters BA, Quaife CJ, Erickson JC, Kelly EJ, Froelick GJ, Zambrowicz BP, Brinster RL & Palmiter RD (1994) Metallothionein-III is expressed in neurons that sequester zinc in synaptic vesicles. J Neurosci 14, 58445857.
  • 8
    Gong YH & Elliott JL (2000) Metallothionein expression is altered in a transgenic murine model of familial amyotrophic lateral sclerosis. Exp Neurol 162, 2736.
  • 9
    Yamada M, Hayashi S, Hozumi I, Inuzuka T, Tsuji S & Takahashi H (1996) Subcellular localization of growth inhibitory factor in rat brain: light and electron microscopic immunohistochemical studies. Brain Res 735, 257264.
  • 10
    Yuguchi T, Kohmura E, Sakaki T, Nonaka M, Yamada K, Yamashita T, Kishiguchi T, Sakaguchi T & Hayakawa T (1997) Expression of growth inhibitory factor mRNA after focal ischemia in rat brain. J Cereb Blood Flow Metab 17, 745752.
  • 11
    Zheng H, Berman NE & Klaassen CD (1995) Chemical modulation of metallothionein I and III mRNA in mouse brain. Neurochem Int 27, 4358.
  • 12
    Tsuji S, Kobayashi H, Uchida Y, Ihara Y & Miyatake T (1992) Molecular cloning of human growth inhibitory factor cDNA and its down-regulation in Alzheimer’s disease. EMBO J 11, 48434850.
  • 13
    Yu WH, Lukiw WJ, Bergeron C, Niznik HB & Fraser PE (2001) Metallothionein III is reduced in Alzheimer’s disease. Brain Res 894, 3745.
  • 14
    Carrasco J, Giralt M, Molinero A, Penkowa M, Moos T & Hidalgo J (1999) Metallothionein (MT)-III: generation of polyclonal antibodies, comparison with MT-I+II in the freeze lesioned rat brain and in a bioassay with astrocytes, and analysis of Alzheimer’s disease brains. J Neurotrauma 16, 11151129.
  • 15
    Erickson JC, Sewell AK, Jensen LT, Winge DR & Palmiter RD (1994) Enhanced neurotrophic activity in Alzheimers-disease cortex is not associated with down-regulation of metallothionein-III (GIF). Brain Res 649, 297304.
  • 16
    Amoureux MC, Van Gool D, Herrero MT, Dom R, Colpaert FC & Pauwels PJ (1997) Regulation of metallothionein-III (GIF) mRNA in the brain of patients with Alzheimer disease is not impaired. Mol Chem Neuropathol 32, 101121.
  • 17
    Sogawa CA, Asanuma M, Sogawa N, Miyazaki I, Nakanishi T, Furuta H & Ogawa N (2001) Localization, regulation, and function of metallothionein-III/growth inhibitory factor in the brain. Acta Med Okayama 55, 19.
  • 18
    Kim D, Kim EH, Kim C, Sun W, Kim HJ, Uhm CS, Park SH & Kim H (2003) Differential regulation of metallothionein-I, II, and III mRNA expression in the rat brain following kainic acid treatment. Neuroreport 14, 679682.
  • 19
    Hozumi I, Inuzuka T, Hiraiwa M, Uchida Y, Anezaki T, Ishiguro H, Kobayashi H, Uda Y, Miyatake T & Tsuji S (1995) Changes of growth inhibitory factor after stab wounds in rat brain. Brain Res 688, 143148.
  • 20
    Hozumi I, Inuzuka T, Ishiguro H, Hiraiwa M, Uchida Y & Tsuji S (1996) Immunoreactivity of growth inhibitory factor in normal rat brain and after stab wounds--an immunocytochemical study using confocal laser scan microscope. Brain Res 741, 197204.
  • 21
    Carrasco J, Penkowa M, Giralt M, Camats J, Molinero A, Campbell IL, Palmiter RD & Hidalgo J (2003) Role of metallothionein-III following central nervous system damage. Neurobiol Dis 13, 2236.
  • 22
    Hidalgo J, Aschner M, Zatta P & Vasák M (2001) Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull 55, 133145.
  • 23
    Chung RS, Adlard PA, Dittmann J, Vickers JC, Chuah MI & West AK (2004) Neuron-glia communication: metallothionein expression is specifically up-regulated by astrocytes in response to neuronal injury. J Neurochem 88, 454461.
  • 24
    Uchida Y, Gomi F, Masumizu T & Miura Y (2002) Growth inhibitory factor prevents neurite extension and the death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging. J Biol Chem 277, 3235332359.
  • 25
    Chung RS, Penkowa M, Dittmann J, King CE, Bartlett C, Asmussen JW, Hidalgo J, Carrasco J, Leung YKJ, Walker AK et al. (2008) Redefining the role of metallothionein within the injured brain – extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J Biol Chem 283, 1534915358.
  • 26
    Faller P (2010) Neuronal growth inhibitory factor (metallothionein-3): reactivity and structure of metal-thiolate clusters. FEBS J 277, 29212930.
  • 27
    Ding ZC, Ni FY & Huang ZX (2010) Neuronal growth inhibitory factor (metallothionein-3): structure-function relationships. FEBS J 277, 29122920.
  • 28
    Erickson JC, Hollopeter G, Thomas SA, Froelick GJ & Palmiter RD (1997) Disruption of the metallothionein-III gene in mice: analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J Neurosci 17, 12711281.
  • 29
    Meloni G, Faller P & Vasak M (2007) Redox silencing of copper in metal-linked neurodegenerative disorders reaction of Zn(7)metallothionein-3 with Cu2+ ions. J Biol Chem 282, 1606816078.
  • 30
    You HJ, Lee KJ & Jeong HG (2002) Overexpression of human metallothionein-III prevents hydrogen peroxide-induced oxidative stress in human fibroblasts. FEBS Lett 521, 175179.
  • 31
    Chung RS, Vickers JC, Chuah MI, Eckhardt BL & West AK (2002) Metallothionein-III inhibits initial neurite formation in developing neurons as well as postinjury, regenerative neurite sprouting. Exp Neurol 178, 112.
  • 32
    Sewell AK, Jensen LT, Erickson JC, Palmiter RD & Winge DR (1995) Bioactivity of metallothionein-3 correlates with its novel beta-domain sequence rather than metal-binding properties. Biochemistry 34, 47404747.
  • 33
    Hasler DW, Jensen LT, Zerbe O, Winge DR & Vasak M (2000) Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein. Biochemistry 39, 1456714575.
  • 34
    Hozumi I, Uchida Y, Watabe K, Sakamoto T & Inuzuka T (2006) Growth inhibitory factor (GIF) can protect from brain damage due to stab wounds in rat brain. Neurosci Lett 395, 220223.
  • 35
    Sakamoto T, Kawazoe Y, Uchida Y, Hozumi I, Inuzuka T & Watabe K (2003) Growth inhibitory factor prevents degeneration of injured adult rat motoneurons. Neuroreport 14, 21472151.
  • 36
    Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430, 631639.
  • 37
    Lovell MA, Robertson JD, Teesdale WJ, Campbell JL & Markesbery WR (1998) Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 158, 4752.
  • 38
    Meloni G, Sonois V, Delaine T, Guilloreau L, Gillet A, Teissie J, Faller P & Vasak M (2008) Metal swap between Zn-7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. Nat Chem Biol 4, 366372.
  • 39
    Holmes C, Boche D, Wilkinson D, Yadegarfur G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW et al. (2008) Long-term effects of Aβ 42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo controlled phase I trial. Lancet 372, 216223.